Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $12.50, for a total transaction of $25,000.00. Following the sale, the president now owns 2,924,467 shares in the company, valued at $36,555,837.50. This represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Songjiang Ma also recently made the following trade(s):

• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

Shares of NASDAQ:GYRE opened at $10.79 on Friday. The company has a fifty day simple moving average of $12.49 and a 200 day simple moving average of $12.66. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $27.10.

Institutional Trading of Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC bought a new stake in shares of Gyre Therapeutics in the third quarter worth $47,000. Barclays PLC increased its stake in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares during the last quarter. State Street Corp increased its stake in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares during the last quarter. Rhumbline Advisers bought a new stake in Gyre Therapeutics during the second quarter valued at $123,000. Finally, Renaissance Technologies LLC bought a new stake in Gyre Therapeutics during the second quarter valued at $166,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.